MétaCan
Menu
Back to cohort
Record W4410981054 · doi:10.1007/s12672-025-02778-8

The safety and efficacy of dabrafenib plus trametinib for patients with brain metastatic melanoma: a systematic review and meta-analysis

2025· review· en· W4410981054 on OpenAlex
Mohammad Amin Habibi, Mohammad Sina Mirjani, Bardia Hajikarimloo, Mohsen Dashti, Afsaneh Ghasemzadeh, Seyed Hesam Hojjat, Mohammad Shahir Eftekhar, Kosar Doraghi, Yalda Ghazizadeh, Fateme Aghaei, Shaghayegh Karami, Mehrshad Edalat, Farhang Rashidi, Sajjad Ahmadpour, Sina Ahmadi

Why this work is in the frame

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

aboutThe title or abstract carries a Canadian signal from the geographic lexicon.
no affNo Canadian affiliation: this work is invisible to an affiliation-only frame.
No Canadian affiliation. An affiliation-only frame, the usual design, would never have seen this work. It is one of the works that make the case for inverting the frame.

Bibliographic record

VenueDiscover Oncology · 2025
Typereview
Languageen
FieldMedicine
TopicBrain Metastases and Treatment
Canadian institutionsnot available
Fundersnot available
KeywordsDabrafenibTrametinibMeta-analysisMedicineOncologyMelanomaInternal medicineMetastatic melanomaCancer researchVemurafenibBiologyMAPK/ERK pathway

Abstract

fetched live from OpenAlex

BACKGROUND: Brain metastases (BM) are common complications of metastatic cancer and typically occur in patients with melanoma. This study aims to investigate the dabrafenib plus trametinib for patients diagnosed with melanoma brain metastasis (MBM). METHOD: This review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). PubMed, Embase, Scopus, and Web of Science were searched until January 1, 2025. Data on the neurological progression-free survival (PFS), overall survival (OS), radiological response rate, whether intracranial and total, and adverse events were collected. Quality assessment of the studies was conducted using the Newcastle-Ottawa Scale (NOS). The STATA version 17.0. has been used for analysis of the outcomes. RESULTS: Eleven studies met the inclusion criteria. Our results showed pooled 6-month OS rate of 76% (95% CI [69-84%]), 1-year OS of 45% (95% CI [38-51%]), 6-month PFS rate of 46% (95% CI [40-52%]), 1-year PFS of 22% (95% CI [13-30%]), disease control rate (DCR) of 71% (95% CI [61-80%]), overall response rate (ORR) of 45% (95% CI [33-57%]), complete response rate (CRR) of 4% (95% CI [0-11%]), partial response rate (PRR) of 47% (95% CI [31-63%]), progressive disease rate (PDR) of 29% (95% CI [13-44%]), and stable disease rate (SDR) of 21% (95% CI [14-27%]). The pooled intracranial CRR, intracranial PRR, intracranial SDR, and intracranial PDR were 4% [95% CI: 1-8%], 42% [95% CI: 32-53%], 24% [95% CI: 18-31%], and 24% [95% CI: 13-34%], respectively. CONCLUSION: These findings underscore the effectiveness of dabrafenib plus trametinib in managing MBM, offering potential benefits in disease control and patient outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.672
Threshold uncertainty score0.915

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0130.002
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.381
Teacher spread0.335 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it